Tempest Therapeutics, Inc.
TPST
$1.92
-$0.02-1.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.88% | -26.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.34% | -54.85% | |||
| Operating Income | -13.34% | 54.85% | |||
| Income Before Tax | -14.53% | 55.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.53% | 55.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.53% | 55.39% | |||
| EBIT | -13.34% | 54.85% | |||
| EBITDA | -13.62% | 55.30% | |||
| EPS Basic | -3.63% | 61.79% | |||
| Normalized Basic EPS | -3.62% | 61.79% | |||
| EPS Diluted | -3.63% | 61.79% | |||
| Normalized Diluted EPS | -3.62% | 61.79% | |||
| Average Basic Shares Outstanding | 10.52% | 16.75% | |||
| Average Diluted Shares Outstanding | 10.52% | 16.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||